SPOTLIGHT: MedImmune touts new FluMist version

MedImmune says that a late-stage trial of a refrigerator-stable version of its FluMist flu vaccine was successful in demonstrating its effectiveness. The Gaithersburg, Maryland, biotech has been sorely disappointed in FluMist sales to date. Story

Suggested Articles

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.

Gilead presented studies at AASLD showing how noninvasive testing and machine learning could improve diagnostics and drug development for NASH.